Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Melanoma/Skin Cancer
What electron beam dose/fractionation would you use for a recurrence basal cell carcinoma of the scalp adjacent to a split thickness skin graft?
Answer from: Radiation Oncologist at Academic Institution
Standard curative dose and fractionation, 6e and 1 cm bolus if superficial lesion, assuming complete healing of the surgical scar.
Sign in or Register to read more
18541
Related Questions
What ENI/lymph node stations would you treat for a locally advanced SCC of the thumb?
Do you obtain MRI for cutaneous SCC with microscopic PNI to assess for gross perineural tumor spread?
Would you consider adjuvant radiation for a patient with recurrent pelvic node melanoma s/p immunotherapy and pelvic lymph node dissection with complete pathological response (only necrotic tissue; no viable melanoma)?
How would you manage a cardiac metastasis from Merkel cell carcinoma?
What are the indications for postoperative radiation for extramammary Paget's disease?
How would you palliate a large, symptomatic vaginal melanoma recurrence with limited small pelvic lymph node metastases?
In patients with multiple basal cell carcinoma lesions on vismodegib, would you hold vismodegib while delivering radiation therapy to one locally advanced BCC lesion that was not amenable to surgery?
How would you treat locally advanced melanoma of the scalp with several in transit lesions and a metastatic lesion to the parotid if the patient is progressing on immunotherapy such as pembrolizumab?
How would you manage a large area of multiple, recurrent cutaneous squamous cell carcinomas of the scalp with ulcerations and non-healing areas despite cryotherapy, multiple Mohs procedures, and 5-FU?
Does the extent of ENE affect your recommendation for concurrent chemotherapy in HPV+ OPSCC patients planned for adjuvant RT?